Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (43)

2024

  1. A road map for the treatment of pediatric diffuse midline glioma

    Cancer Cell

  2. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  3. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  4. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

  5. KDM6A regulates immune response genes in multiple myeloma

    Blood, Vol. 144, Núm. 14, pp. 1508-1520

  6. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

    Cancer Discovery, Vol. 13, Núm. 11, pp. 2370-2393

  2. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  3. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening

    Nature Communications, Vol. 14, Núm. 1

  4. TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory

    Cancer Cell, Vol. 41, Núm. 11, pp. 1911-1926.e8

2022

  1. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

    Nature Immunology, Vol. 23, Núm. 10, pp. 1495-1506

  2. The bone marrow niche regulates redox and energy balance in MLL::AF9 leukemia stem cells

    Leukemia, Vol. 36, Núm. 8, pp. 1969-1979

2021

  1. The transcription factor SLUG uncouples pancreatic cancer progression from the RAF–MEK1/2–ERK1/2 pathway

    Cancer Research, Vol. 81, Núm. 14, pp. 3849-3861

  2. Type 2 immunity is maintained during cancer-associated adipose tissue wasting

    Immunotherapy Advances, Vol. 1, Núm. 1

2020

  1. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    Nature Medicine, Vol. 26, Núm. 6, pp. 878-885

2019

  1. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

    Nature, Vol. 565, Núm. 7737, pp. 43-48

2018

  1. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee

    Biology of Blood and Marrow Transplantation, Vol. 24, Núm. 4, pp. 641-648

2017

  1. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing

    Current Osteoporosis Reports, Vol. 15, Núm. 5, pp. 499-506

  2. ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma

    Cancer Cell, Vol. 32, Núm. 1, pp. 88-100.e6

  3. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936